Detalles de la búsqueda
1.
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Neuroendocrinology
; 107(3): 237-245, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29991024
2.
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
BMC Cancer
; 14: 575, 2014 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25102852
3.
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
BMC Cancer
; 14: 166, 2014 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-24606768
4.
Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Clin Transl Sci
; 15(5): 1131-1142, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35118821
5.
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors.
Cancer Chemother Pharmacol
; 87(5): 621-634, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33507338
6.
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Eur J Drug Metab Pharmacokinet
; 46(3): 343-352, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33852135
7.
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Br J Clin Pharmacol
; 70(1): 57-64, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20642548
8.
Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors.
Cancer Chemother Pharmacol
; 86(2): 181-192, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32623479
9.
Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
AAPS J
; 22(2): 31, 2020 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31975150
10.
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
Cancer Chemother Pharmacol
; 84(1): 41-50, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31006038
11.
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol
; 48(9): 1014-24, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18635756
12.
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
Br J Clin Pharmacol
; 65(3): 355-63, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17953718
13.
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Clin Pharmacokinet
; 45(8): 821-41, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16884320
14.
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.
J Clin Pharmacol
; 46(8): 855-66, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16855070
15.
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol
; 46(1): 88-102, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16397288
16.
Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
J Chromatogr B Analyt Technol Biomed Life Sci
; 837(1-2): 1-10, 2006 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-16631418
17.
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Clin Pharmacokinet
; 55(10): 1251-1269, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27154065
18.
Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.
Clin Cancer Res
; 22(23): 5722-5728, 2016 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27281559
19.
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Breast
; 22(5): 650-6, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23958375
20.
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
J Clin Pharmacol
; 51(2): 189-201, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20354234